JP2007506768A - 肺疾患処置 - Google Patents

肺疾患処置 Download PDF

Info

Publication number
JP2007506768A
JP2007506768A JP2006528240A JP2006528240A JP2007506768A JP 2007506768 A JP2007506768 A JP 2007506768A JP 2006528240 A JP2006528240 A JP 2006528240A JP 2006528240 A JP2006528240 A JP 2006528240A JP 2007506768 A JP2007506768 A JP 2007506768A
Authority
JP
Japan
Prior art keywords
particles
less
mometasone
diameter
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006528240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506768A5 (enExample
Inventor
フランシス エム． カス，
キース ビー． ノロップ，
ウロ エー． パルム，
ヘリバート ダブリュー． スタウディンガー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2007506768A publication Critical patent/JP2007506768A/ja
Publication of JP2007506768A5 publication Critical patent/JP2007506768A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2006528240A 2003-09-26 2004-09-24 肺疾患処置 Pending JP2007506768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50646803P 2003-09-26 2003-09-26
US55159604P 2004-03-09 2004-03-09
PCT/US2004/031444 WO2005030220A1 (en) 2003-09-26 2004-09-24 Pulmonary disease treatment

Publications (2)

Publication Number Publication Date
JP2007506768A true JP2007506768A (ja) 2007-03-22
JP2007506768A5 JP2007506768A5 (enExample) 2007-10-11

Family

ID=34396317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006528240A Pending JP2007506768A (ja) 2003-09-26 2004-09-24 肺疾患処置

Country Status (6)

Country Link
US (3) US20050148563A1 (enExample)
EP (1) EP1667687A1 (enExample)
JP (1) JP2007506768A (enExample)
CA (1) CA2540005A1 (enExample)
MX (1) MXPA06003376A (enExample)
WO (1) WO2005030220A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148262A1 (en) * 2009-06-17 2010-12-23 Mark Rutenberg Treatment of acute pulmonary inflammation induced by cigarette smoking
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510478A (ja) * 1997-03-20 2000-08-15 シェーリング コーポレイション 粉末凝集体の調製
JP2001519397A (ja) * 1997-10-09 2001-10-23 シェーリング コーポレイション 噴霧のためのモメタゾンフロエート懸濁液
JP2002535352A (ja) * 1999-01-28 2002-10-22 シェーリング コーポレイション 凝塊形成用の粒子調製方法
JP2002538110A (ja) * 1999-03-03 2002-11-12 ノバルティス アクチエンゲゼルシャフト 喘息用のフォルモテロールおよびモメタゾンフロエートの組合せ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
SE9801368D0 (sv) * 1998-04-20 1998-04-20 Astra Ab New use
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510478A (ja) * 1997-03-20 2000-08-15 シェーリング コーポレイション 粉末凝集体の調製
JP2001519397A (ja) * 1997-10-09 2001-10-23 シェーリング コーポレイション 噴霧のためのモメタゾンフロエート懸濁液
JP2002535352A (ja) * 1999-01-28 2002-10-22 シェーリング コーポレイション 凝塊形成用の粒子調製方法
JP2002538110A (ja) * 1999-03-03 2002-11-12 ノバルティス アクチエンゲゼルシャフト 喘息用のフォルモテロールおよびモメタゾンフロエートの組合せ

Also Published As

Publication number Publication date
US20110200647A1 (en) 2011-08-18
US20050148563A1 (en) 2005-07-07
EP1667687A1 (en) 2006-06-14
WO2005030220A1 (en) 2005-04-07
MXPA06003376A (es) 2006-06-08
US20080107609A1 (en) 2008-05-08
CA2540005A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
KR100234864B1 (ko) 기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제
Weers et al. The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers
US20100092397A1 (en) Method For Treatment of COPD and Other Pulmonary Diseases
Lipworth Targets for inhaled treatment
WO2000053187A1 (en) New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
US20040009963A1 (en) Use of salmeterol and fluticasone propionate combination
Kässner et al. A review of ipratropium bromide/fenoterol hydrobromide (Berodual®) delivered via Respimat® Soft Mist™ Inhaler in patients with asthma and chronic obstructive pulmonary disease
US20110200647A1 (en) Pulmonary disease treatment
Nayak et al. Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma: a 12-week, randomized, double-blind, placebo-controlled study
HK1038703A1 (zh) 糖皮質類固醇在制備治療輕度/早期copd(慢性阻塞性肺病)的藥物中的應用
JP5154732B2 (ja) 薬剤
Terzano et al. Comparison of the efficacy of beclometasone dipropionate and fluticasone propionate suspensions for nebulization in adult patients with persistent asthma
CN115989032A (zh) 用于吸入施用的组合疗法
Grzelewska-Rzymowska et al. Comparison of the efficacy and safety of high doses of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in steroid-dependent adults with moderate to severe asthma
Pauwels et al. Influence of an extension tube on the bronchodilator efficacy of terbutaline delivered from a metered dose inhaler
Escribano et al. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial
CA2456721C (en) Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
Brand et al. Drug delivery in pediatric patients with asthma: spacer devices vs nebulizers for β2 agonists
Worth A comparison of HFA-BDP Autohaler™ with budesonide Turbuhaler® in asthma control of adult patients with mild to moderately severe disease
CN118903435A (zh) 复方药物制剂及其在医药上的应用
Derom Pulmonary Deposition and Effects of Aerosolized Drugs in Pulmonary Patients
MXPA00009981A (en) Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
HK1169334A1 (en) Inhaled combination product for asthma
CZ20003874A3 (cs) Použití glukokortikosteroidu k výrobě léčiva pro léčbu mírných/počátečních forem chronické obstrukční plicní choroby
HK1169334B (en) Inhaled combination product for asthma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110527

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518